Illumina (NASDAQ:ILMN) Director Keith Meister Sells 131,019 Shares of Stock

Illumina, Inc. (NASDAQ:ILMN) Director Keith Meister sold 131,019 shares of Illumina stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $225.51, for a total value of $29,546,094.69. Following the completion of the transaction, the director owned 1,278,832 shares of the company’s stock, valued at approximately $288,389,404.32. This represents a 9.29% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Illumina Trading Up 1.3%

NASDAQ ILMN traded up $2.85 on Thursday, hitting $227.69. 1,937,136 shares of the stock were exchanged, compared to its average volume of 2,109,322. Illumina, Inc. has a 52-week low of $88.00 and a 52-week high of $231.81. The firm has a market capitalization of $34.38 billion, a P/E ratio of 42.48, a P/E/G ratio of 3.16 and a beta of 1.45. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80. The stock has a fifty day moving average price of $192.98 and a two-hundred day moving average price of $155.18.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The business had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.13 billion. During the same quarter in the previous year, the business earned $1.19 earnings per share. The company’s revenue for the quarter was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Research analysts forecast that Illumina, Inc. will post 5.36 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Empowered Funds LLC raised its position in Illumina by 113.7% during the first quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company’s stock valued at $737,000 after acquiring an additional 4,940 shares in the last quarter. Sivia Capital Partners LLC acquired a new stake in Illumina in the second quarter valued at approximately $621,000. CW Advisors LLC purchased a new stake in shares of Illumina in the second quarter valued at approximately $275,000. Marshall Wace LLP raised its stake in shares of Illumina by 49.0% during the 2nd quarter. Marshall Wace LLP now owns 59,645 shares of the life sciences company’s stock worth $5,691,000 after buying an additional 19,618 shares during the period. Finally, Cresset Asset Management LLC raised its stake in shares of Illumina by 30.9% during the 2nd quarter. Cresset Asset Management LLC now owns 7,404 shares of the life sciences company’s stock worth $706,000 after buying an additional 1,748 shares during the period. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. Evercore reaffirmed an “outperform” rating on shares of Illumina in a research report on Monday, July 6th. Deutsche Bank Aktiengesellschaft downgraded Illumina to a “hold” rating in a research report on Wednesday, August 5th. Zacks Research upgraded shares of Illumina from a “hold” rating to a “strong-buy” rating in a report on Monday, August 3rd. Stifel Nicolaus lifted their price target on shares of Illumina from $155.00 to $225.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating and set a $215.00 target price on shares of Illumina in a research report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $188.40.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.